HanAll Biopharma Reports Q4 Operating Profit of 2.8 Billion KRW, Up 99.8% YoY
[Asia Economy Reporter Eunmo Koo] HanAll Biopharma announced on the 16th that its consolidated operating profit for the fourth quarter of last year was tentatively estimated at 2.824 billion KRW, a 99.8% increase compared to the same period last year. During the same period, sales increased by 12.5% to 26.141 billion KRW, while net profit decreased by 353.4% to 6.879 billion KRW.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Opening a Bank Account in Korea Is Too Difficult..."It Costs 150,000 Won Just to Open a Child's Account or Check Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
